A subgroup analysis of Medivir´s phase II study of MIV-711 for osteoarthritis shows statistically significant reduction in OA pain
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that an article entitled “Symptomatic and structural benefit of cathepsin K inhibition by MIV-711 in a subgroup with unilateral pain: post-hoc analysis of a randomised phase 2a clinical trial” by Bihlet, A.R. et al has been published in Clinical and Experimental Rheumatology 2022 (Articles In Press CER15118, https://www.clinexprheumatol.org/).Extensive pain in one knee, other than the target-knee for which pain is measured, may confound osteoarthritis (OA) pain outcomes. This exploratory analysis focused on a subgroup